Vita Therapeutics bolsters leadership

By The Science Advisory Board staff writers

March 31, 2022 -- Cell engineering firm Vita Therapeutics has added three new senior vice presidents to its executive lineup.

The new hires include: Amy Wesa, PhD, as senior vice president of preclinical and translational research; Alexandra (Xana) Capela, PhD, as senior vice president of regulatory and investigational new drug application strategy; and Michael Kuo as senior vice president of manufacturing.

In addition, Vita has appointed Brown Advisory Chief Financial Officer and Chief Operating Officer David Churchill to its board of directors.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.